Physician profile
Daniel Kaswan
NPI 1942326418
$21,280.22
in general payments reported to CMS, 2019-2025
10 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $5,630 · 2021: $4,198 · 2022: $4,090 · 2023: $2,665 · 2024: $4,007 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,038 · Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,037.50 |
| Food and Beverage | $1,081.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,575.33 | 2021-2024 | |
| Allergan, INC. | $6,567.33 | 2019-2021 | |
| Viiv Healthcare Company | $610.87 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $139.67 | 2019-2025 | |
| Janssen Biotech, INC. | $117.59 | 2019-2022 | |
| Shionogi INC | $91.59 | 2023-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $62.03 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $58.36 | 2019 | |
| Aimmune Therapeutics, INC. | $31.62 | 2025 | Vowst |
| Insmed, INC. | $25.83 | 2025 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kaswan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.